Growing up, I wanted to be an architect. It wasn’t until I realized how much math was involved that those initial dreams died a…
An Offer He Couldn’t Refuse: Reporter Phil Gutis interviews Joanne Pike on her first day as CEO of the Alzheimer’s Association As any reporter…
Reporter Phil Gutis is living with Alzheimer’s. So is his dog, Bea. One day, the same approach to treatment might help them both. Sometimes…
Reporter Phil Gutis, a board member for emerging Alzheimer’s advocacy group Voices of Alzheimer’s, takes a hard look at what more the Centers for…
At this year’s AAIC, the developer of an Alzheimer’s blood test debuts promising data, while the Alzheimer’s Association warns new blood-based biomarkers aren’t quite…
Image: Phil Gutis receives an aducanumab infusion while carrying out his “silly shoe challenge.” Phil Gutis reflects on the significance of participating in the…
“It’s Time for More Time” With the #MoreTime campaign, the Alzheimer’s Association has gone all in on aducanumab, the controversial new Alzheimer’s drug produced…
A new book by Dr. Jason Karlawish shares largely untold stories the history of the Alzheimer’s crisis, discussing the science, missed opportunities, and reasons…
Drugmaker Cassava believes its experimental Alzheimer’s therapy, which sent the company’s stock values surging with a recent phase 2 study announcement, could beat Biogen’s…
Biogen’s Alzheimer’s drug aducanumab encounters another bump in the road as the FDA delays its approval decision. The Federal Drug Administration has given itself…
In an unexpected twist, the advisory committee that convened today on the experimental Alzheimer’s treatment aducanumab overwhelmingly said that drugmaker Biogen has failed to…
A survey of all drugs currently in clinical trials for Alzheimer’s disease found 121 unique therapies being tested in 136 Alzheimer’s drug trials. That…
Every fall, the reminders to get a flu shot can become so pervasive they can be easily ignored: “Yeah, yeah,” you say. “I need…
In another step toward what could be the first treatment for early stage Alzheimer’s, Biogen and Eisai today said they have completed an application…
Hours feel like days. Days feel like months. And months? Well they can feel like a decade. Particularly when you are awaiting the restart…